{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:48:04Z","timestamp":1791902884461,"version":"4.3.4"},"reference-count":22,"publisher":"Walter de Gruyter GmbH","license":[{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    This research introduces a first-in-class high-performance liquid chromatography with fluorescence detection (HPLC-FD) method for the reliable quantification of ROS in plasma. The method relies on the native fluorescence of ROS, with excitation and emission set at 280 nm and 340 nm, resp. Sample preparation involved a simple one-step protein precipitation with methanol. Chromatographic resolution of ROS and pemigatinib (PEM), which served as the internal standard (IS), was achieved using Zorbax Eclipse Plus C18 HPLC column. The mobile phase consisted of methanol and formate buffer solution. The method was validated in compliance with ICH M10 guidelines. It showed linearity across concentration range of 50\u20131,500 ng mL\n                    <jats:sup>\u22121<\/jats:sup>\n                    (\n                    <jats:italic>R<\/jats:italic>\n                    \u00b2 = 0.9991), with a lower limit of quantitation of 50 ng mL\n                    <jats:sup>\u22121<\/jats:sup>\n                    . Accuracy ranged from 96.8 to 103.4 %, and intra- and inter-day precision (RSD) were between 3.2 and 6.1 %. The method was successfully applied to quantify ROS in plasma samples from rats following administration of a single oral dose (25 mg kg\n                    <jats:sup>\u22121<\/jats:sup>\n                    ), enabling the determination of key pharmacokinetic parameters, including\n                    <jats:italic>C<\/jats:italic>\n                    <jats:sub>max<\/jats:sub>\n                    (361.31 ng mL\n                    <jats:sup>\u22121<\/jats:sup>\n                    ),\n                    <jats:italic>t<\/jats:italic>\n                    <jats:sub>max<\/jats:sub>\n                    (1.75 h,\n                    <jats:italic>t<\/jats:italic>\n                    <jats:sub>\u00bd<\/jats:sub>\n                    (2.867 h),\n                    <jats:italic>V<\/jats:italic>\n                    <jats:sub>d<\/jats:sub>\n                    (0.077 L kg\n                    <jats:sup>\u22121<\/jats:sup>\n                    ),\n                    <jats:italic>CL<\/jats:italic>\n                    (0.018 L h\n                    <jats:sup>\u22121<\/jats:sup>\n                    kg\n                    <jats:sup>\u22121<\/jats:sup>\n                    ),\n                    <jats:italic>AUC<\/jats:italic>\n                    (ng h mL\n                    <jats:sup>\u22121<\/jats:sup>\n                    ) and and\n                    <jats:italic>MRT<\/jats:italic>\n                    (h). The greenness and practical applicability of the method were confirmed using four comprehensive independent metric tools. In comparison to previously reported bioanalytical approaches, the proposed method offers several practical advantages, such as reduced complexity and cost, a shorter run time, full validation, established greenness, and suitability for the clinical laboratory setting.\n                  <\/jats:p>","DOI":"10.2478\/acph-2026-0029","type":"journal-article","created":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:21:20Z","timestamp":1791901280000},"source":"Crossref","is-referenced-by-count":0,"title":["First-in-class HPLC-fluorescence method for quantification of roscovitine in plasma: Greenness assessment and application to pharmacokinetic studies in rats"],"prefix":"10.2478","author":[{"given":"Ibrahim A.","family":"Darwish","sequence":"first","affiliation":[{"name":"1 Department of Pharmaceutical Chemistry , College of Pharmacy, King Saud University , P.O. Box 2457 Riyadh , Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nourah Z.","family":"Alzoman","sequence":"additional","affiliation":[{"name":"1 Department of Pharmaceutical Chemistry , College of Pharmacy, King Saud University , P.O. Box 2457 Riyadh , Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2026,10,13]]},"reference":[{"key":"2026101314060982010_j_acph-2026-0029_ref_001","doi-asserted-by":"crossref","unstructured":"H. K. Alhashimi, M. A. A. Najm and H. N. K. AL-Salman, Targeting cyclin-dependent kinases (CDKs) for cancer therapy: An in-depth review of molecular candidates, their synthesis, evaluation, and future directions, Farm. Polska 81 (2025) 489\u2013499; https:\/\/doi.org\/10.32383\/farmpol\/218224","DOI":"10.32383\/farmpol\/218224"},{"key":"2026101314060982010_j_acph-2026-0029_ref_002","doi-asserted-by":"crossref","unstructured":"N. Raje, S. Kumar, T. Hideshima, A. Roccaro, K. Ishitsuka, H. Yasui, N. Shiraishi, D. Chauhan, N. C. Munshi, S. R. Green and K. C. Anderson, Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma, Blood 106 (2005) 1042\u20131047; https:\/\/doi.org\/10.1182\/blood-2005-01-0320","DOI":"10.1182\/blood-2005-01-0320"},{"key":"2026101314060982010_j_acph-2026-0029_ref_003","doi-asserted-by":"crossref","unstructured":"K. Bettayeb, D. Baunb\u00e6k, C. Delehouze, N. Loa\u00ebc, A. J. Hole, S. Baumli, J. A. Endicott, S. Douc-Rasy, J. B\u00e9nard, N. Oumata, H. Galons and L. Meijer, CDK inhibitors roscovitine and CR8 trigger Mcl-1 down-regulation and apoptotic cell death in neuroblastoma cells, Genes Cancer 1 (2010) 369\u2013380; https:\/\/doi.org\/10.1177\/1947601910369817","DOI":"10.1177\/1947601910369817"},{"key":"2026101314060982010_j_acph-2026-0029_ref_004","unstructured":"J. Cicenas, K. Kalyan, A. Sorokinas, E. Stankunas, J. Levy, I. Meskinyte, V. Stankevicius, A. Kaupinis and M. Valius, Roscovitine in cancer and other diseases, Ann. Transl. Med. 3(10) (2015) Article ID 135 (12 pages); https:\/\/doi.org\/10.3978\/j.issn.2305-5839.2015.03.61"},{"key":"2026101314060982010_j_acph-2026-0029_ref_005","doi-asserted-by":"crossref","unstructured":"M. S. Alsalhi, M. Al-Outaibi and I. A. Darwish, Development of three innovative green microwell spectrometric methods with high throughput for determination of seleciclib in its bulk form and capsules, Sust. Chem. Pharm. 37 (2024) Article ID 101443; https:\/\/doi.org\/10.1016\/j.scp.2024.101443","DOI":"10.1016\/j.scp.2024.101443"},{"key":"2026101314060982010_j_acph-2026-0029_ref_006","doi-asserted-by":"crossref","unstructured":"I. A. Darwish and N. Z. Alzoman, Development of green and high throughput microplate reader--assisted universal microwell spectrophotometric assay for direct determination of tyrosine kinase inhibitors in their pharmaceutical formulations irrespective the diversity of their chemical structures, Molecules 28 (2023) Article ID 4049 (19 pages); https:\/\/doi.org\/10.3390\/molecules28104049","DOI":"10.3390\/molecules28104049"},{"key":"2026101314060982010_j_acph-2026-0029_ref_007","doi-asserted-by":"crossref","unstructured":"G. Xie, M. Liao, B. Wang and C. Zhang, Determination of seliciclib enantiomeric purity by HPLC on chiral stationary phase, Chromatographia 79 (2016) 641\u2013646; https:\/\/doi.org\/10.1007\/s10337-016-3067-3","DOI":"10.1007\/s10337-016-3067-3"},{"key":"2026101314060982010_j_acph-2026-0029_ref_008","doi-asserted-by":"crossref","unstructured":"P. Ors\u00e1g, L. H. I. Fojt, J. Coufal, V. Br\u00e1zda and M. Fojta, Voltammetric behavior of a candidate anti-cancer drug seliciclib at carbon electrodes in aqueous buffers and a cell culture medium, Monatsh. Chem. 150 (2019) 461\u2013467; https:\/\/doi.org\/10.1007\/s00706-018-2333-5","DOI":"10.1007\/s00706-018-2333-5"},{"key":"2026101314060982010_j_acph-2026-0029_ref_009","doi-asserted-by":"crossref","unstructured":"M. Vita, L. Meurling, T. Pettersson, M. Cruz-Sid\u00e9n, \u00c5. Sid\u00e9n and M. Hassan, Analysis of roscovitine using novel high performance liquid chromatography and UV-detection method: Pharmacokinetics of roscovitine in rat, J. Pharm. Biomed. Anal. 34(2) (2004) 425\u2013431; https:\/\/doi.org\/10.1016\/S0731-7085(03)00534-X","DOI":"10.1016\/S0731-7085(03)00534-X"},{"key":"2026101314060982010_j_acph-2026-0029_ref_010","doi-asserted-by":"crossref","unstructured":"M. Vita, M. Abdel-Rehim, S. Olofsson, Z. Hassan, L. Meurling, A. Sid\u00e9n, M. Sid\u00e9n, T. Pettersson and M. Hassan, Tissue distribution, pharmacokinetics and identification of roscovitine metabolites in rat, Pharm. Sci. 25(1) (2005) 91\u2013103; https:\/\/doi.org\/10.1016\/j.ejps.2005.02.001","DOI":"10.1016\/j.ejps.2005.02.001"},{"key":"2026101314060982010_j_acph-2026-0029_ref_011","doi-asserted-by":"crossref","unstructured":"M. Vita, P. Skansen, M. Hassan and M. Abdel-Rehim, Development and validation of a liquid chromatography and tandem mass spectrometry method for determination of roscovitine in plasma and urine samples utilizing on-line sample preparation, J. Chromatogr. B 817 (2005) 303\u2013307; https:\/\/doi.org\/10.1016\/j.jchromb.2004.12.018","DOI":"10.1016\/j.jchromb.2004.12.022"},{"key":"2026101314060982010_j_acph-2026-0029_ref_012","doi-asserted-by":"crossref","unstructured":"M. Karady, O. Nov\u00e1k, A. Horna, M. Strnad and K. Dole\u017eal, High performance liquid chromatography-electrochemistry-electrospray ionization mass spectrometry (HPLC\/EC\/ESI-MS) for detection and characterization of roscovitine oxidation products, Electroanalysis 23 (2011) 2898\u20132905; https:\/\/doi.org\/10.1002\/elan.201100383","DOI":"10.1002\/elan.201100383"},{"key":"2026101314060982010_j_acph-2026-0029_ref_013","doi-asserted-by":"crossref","unstructured":"A. Y. Sayed, N. Y. Khalil, A. Almomen, A. A. Almehizia and I. A. Darwish, A highly sensitive nonextraction-assisted HPLC method with fluorescence detection for quantification of duvelisib in plasma samples and its application to pharmacokinetic study in rats, Drug Des. Dev. Ther. 15 (2021) 2667\u20132677; https:\/\/doi.org\/10.2147\/dddt.s318714","DOI":"10.2147\/DDDT.S318714"},{"key":"2026101314060982010_j_acph-2026-0029_ref_014","unstructured":"ICH, International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, ICH Harmonised Guideline, Bioanalytical Method Validation and Study Sample Analysis: M10, ICH, Geneva 2022."},{"key":"2026101314060982010_j_acph-2026-0029_ref_015","doi-asserted-by":"crossref","unstructured":"A. Ga\u0142uszka, P. Konieczka, Z. M. Migaszewski and J. Namie\u015bnik, Analytical eco-scale for assessing the greenness of analytical procedures, Trends Anal. Chem. 37 (2012) 61\u201372; https:\/\/doi.org\/10.1016\/j.trac.2012.03.013","DOI":"10.1016\/j.trac.2012.03.013"},{"key":"2026101314060982010_j_acph-2026-0029_ref_016","doi-asserted-by":"crossref","unstructured":"J. P\u0142otka-Wasylka, A new tool for the evaluation of the analytical procedure: Green analytical procedure index, Talanta 181 (2018) 204\u2013209; https:\/\/doi.org\/10.1016\/j.talanta.2018.01.013","DOI":"10.1016\/j.talanta.2018.01.013"},{"key":"2026101314060982010_j_acph-2026-0029_ref_017","doi-asserted-by":"crossref","unstructured":"F. Pena-Pereira, W. Wojnowski and M. Tobiszewski, AGREE-analytical greenness metric approach and software, Anal. Chem. 92 (2020) 10076\u201310082; https:\/\/doi.org\/10.1021\/acs.analchem.0c01887","DOI":"10.1021\/acs.analchem.0c01887"},{"key":"2026101314060982010_j_acph-2026-0029_ref_018","doi-asserted-by":"crossref","unstructured":"N. Manousi, W. Wojnowski, J. P\u0142otka-Wasylka and V. Samanidou, Blue applicability grade index (BAGI) and software: a new tool for the evaluation of method practicality, Green Chem. 25 (2023) 7598\u20137604; https:\/\/doi.org\/10.1039\/D3GC02347H","DOI":"10.1039\/D3GC02347H"},{"key":"2026101314060982010_j_acph-2026-0029_ref_019","doi-asserted-by":"crossref","unstructured":"J. P\u0142otka-Wasylka and J. Namie\u015bnik (Eds.), Green Analytical Chemistry: Past, Present and Perspectives, Springer Nature Singapore Pte Ltd., Singapore 2019; https:\/\/doi.org\/10.1007\/978-981-13-9105-7","DOI":"10.1007\/978-981-13-9105-7"},{"key":"2026101314060982010_j_acph-2026-0029_ref_020","doi-asserted-by":"crossref","unstructured":"I. A. Darwish, N. Z. Alzoman and M. S. Alsalhi, A green and highly sensitive microwell spectrofluorimetric method with high throughput for the determination of pemigatinib based on dual fluorescence enhancement by photoinduced electron transfer blocking and micellization: Application to the analysis of tablets, content uniformity testing, and human plasma, Luminescence 39(6) (2024) e4813; https:\/\/doi.org\/10.1002\/bio.4813","DOI":"10.1002\/bio.4813"},{"key":"2026101314060982010_j_acph-2026-0029_ref_021","doi-asserted-by":"crossref","unstructured":"L. Meijer, G. Hery-Arnaud, C. Leven, E. Nowak, S. Hillion, Y. Renaudineau, I. Durieu, R. Chiron, A. Prevotat, I. Fajac, D. Hubert, M. Murris-Espin, S. Huge, I. Danner-Boucher, B. Ravoninjatovo, S. Leroy, J. Macey, T. Urban, G. Rault, D. Mottier and R. Le Berre, Safety and pharmacokinetics of roscovitine (seliciclib) in cystic fibrosis patients chronically infected with Pseudomonas aeruginosa, a randomized, placebo-controlled study, J. Cyst. Fibrosis 21 (2022) 529\u2013536; https:\/\/doi.org\/10.1016\/j.jcf.2021.10.013","DOI":"10.1016\/j.jcf.2021.10.013"},{"key":"2026101314060982010_j_acph-2026-0029_ref_022","doi-asserted-by":"crossref","unstructured":"E. M. Blais, K. D. Rawls, B. V. Dougherty, Z. I. Li, G. L. Kolling, P. Ye, A. Wallqvist and J. A. Papin, Reconciled rat and human metabolic networks for comparative toxicogenomics and biomarker predictions, Nat. Commun. 8 (2017) Article ID 14250 (15 pages); https:\/\/doi.org\/10.1038\/ncomms14250","DOI":"10.1038\/ncomms14250"}],"container-title":["Acta Pharmaceutica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/acph-2026-0029","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:21:24Z","timestamp":1791901284000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/acph-2026-0029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,13]]},"references-count":22,"alternative-id":["10.2478\/acph-2026-0029"],"URL":"https:\/\/doi.org\/10.2478\/acph-2026-0029","relation":{},"ISSN":["1846-9558"],"issn-type":[{"value":"1846-9558","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,13]]}}}